of some Janssen products, such as mebendazole. In 1985, now operating as Xian-Janssen Pharmaceuticals, a new large factory was opened in the city of Xi'an, also in Shaanxi province. Drugs developed Janssen Pharmaceuticals has developed and brought to the market about 70 new active substances (NCE), of which the most well-known are (name may differ): Imodium (against diarrhoea. Active substance: loperamide) Motilium (against flatulence and bowel impairments. Active substance: domperidone) Reminyl (against Alzheimer's disease (dementia). Active substance: galantamine) Daktarin (against fungal infections. Active substance: miconazole) Nizoral (against dandruff, Active substance: ketoconazole) Duragesic (fentanyl patch for pain suppression. Active substance: fentanyl) Vermox (against intestinal worms. Active substance: mebendazole) Risperdal (antipsychotic, against mental illness such as schizophrenia. Active substance: risperidone) WHO Model List of Essential Medicines Eight original Janssen drugs have been included on the WHO Model List of Essential Medicines: Imodium (loperamide) Haldol (haloperidol) Ergamisol (levamisole) Daktarin (miconazole) Vermox (mebendazole) Nizoral (ketoconazole) (Removed in 2005) Risperdal (risperidone) Sirturo (bedaquiline) - an diarylquinoline anti-tuberculosis drug, discovered by Koen Andries and his team, which promises a shorter and simpler treatment for multi-drug-resistant tuberculosis (MDR-TB). Centocor products In 1984, Centocor developed their first product approved by the U.S. Food and Drug Administration (FDA) — a diagnostic test used to detect the rabies virus. In 1998, the company launched its top-selling monoclonal antibody Remicade (infliximab) for its first FDA approved indication in Crohn's disease. Subsequently, Remicade's market has expanded with approvals for rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, ulcerative colitis, and pediatric Crohn's disease. Remicade was approved for plaque psoriasis in September 2006. Centocor also markets ReoPro (abciximab), a biologic agent indicated as an adjunct to coronary angioplasty (PTCA). In 2009, the U.S. FDA approved Simponi, a human monoclonal antibody for treatment for arthritis, which was co-developed with Medarex, Inc. Risperdal deception In 2004, the United States Department of Justice began investigating sales practices surrounding the antipsychotic drug risperidone (Risperdal). In 2010, the agency joined a whistleblower suit alleging that despite being warned by the U.S. Food and Drug Administration not to promote Risperdal as effective and safe for elderly patients, in whom it was known to be associated with early death, Johnson & Johnson and Janssen Pharmaceuticals paid pharmacists at Omnicare, the largest supplier of pharmaceuticals to nursing homes, tens of millions of dollars in bribes and kickbacks to promote the drug to physicians for this unapproved use. The lawsuit resulted in a 2012